• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Redmile Group, Llc

    4/22/26 9:51:32 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FATE alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last)(First)(Middle)
    900 LARKSPUR LANDING CIRCLE,
    SUITE 270

    (Street)
    LARKSPUR CALIFORNIA 94939

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    FATE THERAPEUTICS INC [ FATE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/20/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock04/20/2026J(1)8,977,624D$0(1)0D(2)(5)
    Common Stock04/20/2026J(3)8,977,624A$0(1)12,884,277(4)ISee Footnotes(4)(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Pre-Funded Warrants to Purchase Common Stock$0.00104/20/2026J(1)3,691,324 (6) (6)Common Stock3,691,324$0(1)0D(2)(5)
    Pre-Funded Warrants to Purchase Common Stock$0.00104/20/2026J(3)3,691,324 (6) (6)Common Stock3,691,324$0(1)3,893,674(4)ISee Footnotes(4)(5)
    Cash-settled Swaps$3.02(7)04/20/2026J(9)266,280 (8)(10) (11)Common Stock266,280$0(9)0D(2)(5)
    Cash-settled Swaps$3.02(7)04/20/2026J(3)(9)266,280 (8)(10) (11)Common Stock266,280$0(9)502,769(4)ISee Footnotes(4)(5)
    Class A Convertible Preferred Stock(12)(13)04/20/2026J(1)162,013 (12)(14) (14)Common Stock810,065(13)$0(1)0D(2)(5)
    Class A Convertible Preferred Stock(12)(13)04/20/2026J(3)162,013 (12)(14) (14)Common Stock810,065(13)$0(1)2,755,086(4)ISee Footnotes(4)(5)
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last)(First)(Middle)
    900 LARKSPUR LANDING CIRCLE,
    SUITE 270

    (Street)
    LARKSPUR CALIFORNIA 94939

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    XDirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Green Jeremy

    (Last)(First)(Middle)
    C/O REDMILE GROUP, LLC (NY OFFICE)
    45 W. 27TH STREET, FLOOR 11

    (Street)
    NEW YORK NEW YORK 10001

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    XDirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    RedCo II Master Fund, L.P.

    (Last)(First)(Middle)
    C/O REDMILE GROUP, LLC
    900 LARKSPUR LANDING CIRCLE, SUITE 270

    (Street)
    LARKSPUR CALIFORNIA 94939

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    XDirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. In connection with an internal reorganization of RedCo II Master Fund, L.P. ("RedCo II"), which is one of the private investment vehicles managed by Redmile Group, LLC ("Redmile"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the "SPVs"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the "Common Stock"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green.
    2. The reported securities were directly owned by RedCo II.
    3. This transaction is reported to reflect that two of the Reporting Persons (Redmile and Jeremy Green, its principal) retain an indirect beneficial ownership in the securities transacted in, as reported in the row above. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green.
    4. The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the "Redmile Clients"), excluding RedCo II but including the SPVs.
    5. Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
    6. The pre-funded warrants ("Warrants") are exercisable by the holder at any time until fully exercised at an exercise price per share of $0.001, subject to a limitation on the right of the Issuer to issue Common Stock if and to the extent that such exercise would cause the holder and its affiliates to beneficially own in the aggregate more than 14.99% of the combined voting power of all of the securities of the Issuer outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Warrants have no expiration date.
    7. Represents the reference price associated with the swap agreements.
    8. Certain Redmile Clients are parties to swap agreements with counterparties. Each notional share subject to each swap agreement represents the economic equivalent of one share of Common Stock. These agreements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparties thereto to acquire, hold, vote or dispose of any securities of the Issuer.
    9. In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure.
    10. The Reporting Persons disclaim any beneficial ownership in securities that may be referenced in such swap agreements or that may be held from time to time by any counterparties to the agreements.
    11. The Redmile Clients that are parties to the swap agreements have the right to close out each swap at any time. Upon settlement of the various swap agreements, either (i) the counterparty will pay to the Redmile Clients in cash an amount determined in part by reference to any increase between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement or (ii) the Redmile Clients will pay to the counterparty in cash an amount determined in part by reference to any decrease between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement.
    12. The Class A Preferred Stock is convertible into Common Stock, in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the "Certificate of Designation") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66.
    13. The one-for-five conversion rate is taken into account in the amount of underlying Common Stock involved in the transaction listed under Column 7 of Table II.
    14. The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date.
    By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC04/22/2026
    /s/ Jeremy Green, Managing Member of RedCo II (GP), LLC, the General Partner of RedCo II Master Fund, L.P.04/22/2026
    /s/ Jeremy Green04/22/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $FATE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FATE

    DatePrice TargetRatingAnalyst
    10/31/2025$5.00Neutral → Buy
    H.C. Wainwright
    10/27/2025$7.00Neutral → Outperform
    Wedbush
    11/18/2024Underperform → Neutral
    BofA Securities
    6/17/2024$4.00 → $6.00Neutral → Overweight
    Piper Sandler
    3/27/2023$6.00Equal Weight
    Wells Fargo
    1/24/2023$115.00 → $7.00Buy → Neutral
    H.C. Wainwright
    1/6/2023$20.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    1/6/2023$71.00 → $12.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $FATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Redmile Group, Llc

    4/A - FATE THERAPEUTICS INC (0001434316) (Issuer)

    4/23/26 9:00:13 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Redmile Group, Llc

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    4/22/26 9:51:32 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Tahl Cindy was granted 100,000 shares, increasing direct ownership by 26% to 487,081 units (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    1/16/26 4:03:32 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

    SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that preclinical data from the Company's next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research Annual Meeting, being held in San Diego, CA on April 17-22, 2026. The Company has been selected to participate in a poster presentation featuring preclinical data from FT839, its next generation, 13-point edit

    4/16/26 9:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

    SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in five upcoming investor conferences in the second quarter of 2026. 25th Annual Needham Virtual Healthcare Conference Location: Virtual Date: April 14th   Bank of America Healthcare Conference 2026 Location: Encore at the Wynn - Las Vegas, NV         Date: May 13th H.C. Wainwright 4th Annual BioConnect Investor Conference  Location: Nasdaq

    4/9/26 9:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering in

    4/2/26 4:05:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.

    SCHEDULE 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    4/22/26 9:47:24 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fate Therapeutics Inc.

    SCHEDULE 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    3/26/26 6:21:12 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Fate Therapeutics Inc.

    10-K - FATE THERAPEUTICS INC (0001434316) (Filer)

    2/26/26 9:07:51 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    12/26/24 9:00:15 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    12/28/23 9:30:16 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fate Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Fate Therapeutics from Neutral to Buy and set a new price target of $5.00

    10/31/25 8:14:08 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics upgraded by Wedbush with a new price target

    Wedbush upgraded Fate Therapeutics from Neutral to Outperform and set a new price target of $7.00

    10/27/25 8:29:46 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics upgraded by BofA Securities

    BofA Securities upgraded Fate Therapeutics from Underperform to Neutral

    11/18/24 3:46:41 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Financials

    Live finance-specific insights

    View All

    Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

    First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS

    5/9/24 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

    SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order

    5/6/24 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

    CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA

    2/26/24 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Leadership Updates

    Live Leadership Updates

    View All

    Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

    SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025. Mr. Adawi brings to the Company more than 20 years of financial leadership experience in the life sciences industry, including over 10 years serving as CFO across innovative life science companies, with deep domain expertise in autoimmune diseases, including lupus. "We are excited to wel

    10/14/25 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

    SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

    5/30/25 4:30:14 PM ET
    $FATE
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Announces Leadership Transition

    Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala

    11/29/24 1:05:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    11/14/24 7:50:18 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    10/25/24 9:37:07 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Fate Therapeutics Inc. (Amendment)

    SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    3/25/24 5:15:23 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care